Semaglutide Leads Weight Loss in Schizophrenia Patients
A network meta-analysis of 95 trials ranks GLP-1 drugs highest for weight loss among antipsychotic-treated patients with schizophrenia.
Updated on Nov. 2, 2026 in Weight Loss
Live Poll
Should insurance plans be required to cover GLP-1 weight-loss drugs for patients with mental illness?
Semaglutide was associated with the largest weight loss among treatments examined for antipsychotic-treated patients with schizophrenia, according to a network meta-analysis of 95 trials. Researchers say the findings point to emerging options for a population facing metabolic side effects from long-standing medications.
Why it matters
Antipsychotic-linked weight gain contributes to medication nonadherence, low self-esteem, reduced quality of life and worse cognitive functioning. Life expectancy for people with serious mental illness is roughly 10 to 25 years shorter than the general population.
In the analysis of 39 interventions across 5,898 participants, semaglutide produced a mean weight reduction of 10.98 kg versus placebo, more than double liraglutide's 5.43 kg. Long-term durability of these effects in antipsychotic-treated patients was not addressed.
The players
Agarwal
Lead researcher affiliated with the University of Toronto Centre for Addiction and Mental Health, who led the network meta-analysis.
The details
Researchers performed a network meta-analysis of 95 trials and identified treatments associated with the greatest weight loss in antipsychotic-treated patients with schizophrenia, based on moderate-certainty evidence. GLP-1 agents showed slightly higher rates of mild-to-moderate gastrointestinal side effects, while discontinuation rates were not significantly higher than placebo.
Timeline
Antipsychotics have been a mainstay treatment for schizophrenia for decades.
Clinicians and patients long viewed antipsychotic metabolic side effects as inevitable.
In recent years, GLP-1 agents such as semaglutide have shifted the field.
Health Landscape
The findings extend the GLP-1 weight-loss evidence base that emerged from general-population obesity treatment into a population where antipsychotic-driven weight gain has long been treated as unavoidable. Field-level shifts in neuroendocrinology are now prompting reconsideration of metabolic care in serious mental illness.
Patients taking antipsychotics who are concerned about weight gain may wish to discuss metabolic monitoring and treatment options with their clinicians. Access to GLP-1 weight-loss drugs for patients with psychosis remains limited by insurance coverage restrictions.
The takeaway
Metabolic side effects of antipsychotics are a modifiable part of care, and emerging evidence suggests GLP-1 agents may help address them. Patients and clinicians should review weight management alongside psychiatric treatment.
Further reading
Explore more on Weight Loss strategies and the medications being studied for them.
Live Poll
Should insurance plans be required to cover GLP-1 weight-loss drugs for patients with mental illness?
